Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.47 -0.42 (-0.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,472,334
Open 47.58
Bid (Size) 47.25 (300)
Ask (Size) 47.80 (1,000)
Prev. Close 47.89
Today's Range 47.10 - 47.63
52wk Range 44.62 - 60.12
Shares Outstanding 1,250,690,553
Dividend Yield 4.66%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation
In a bold move to solidify its dominance in the cardiometabolic market, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, that it has entered into a definitive agreement to acquire Ventyx... 
Via MarketMinute
Topics Intellectual Property
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers ↗
Via Stocktwits

Performance

YTD
-1.6%
-1.6%
1 Month
+0.1%
+0.1%
3 Month
-5.1%
-5.1%
6 Month
-2.4%
-2.4%
1 Year
-3.8%
-3.8%

More News

Read More
News headline image
Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
Via MarketMinute
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
Via MarketMinute
Topics Intellectual Property
News headline image
BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Via PredictStreet
Topics Initial Public Offering Intellectual Property
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
Trade War 2.0: Markets Braced as Trump’s 2026 Tariff ‘Salvos’ Reshape the Global Supply Chain
Via MarketMinute
Topics Economy Government World Trade
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
News headline image
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗
Via Stocktwits
Topics Economy Government
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
Via PredictStreet
News headline image
The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Dynavax Stock Soared Today ↗
Via The Motley Fool
News headline image
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition
Via PredictStreet
Topics Economy
News headline image
Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring
Via MarketMinute
Topics Intellectual Property
News headline image
Why Did Dynavax Stock Surge 38% In Premarket Today? ↗
Via Stocktwits

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?
Yes, Sanofi - American Depositary Shares is publicly traded.
What exchange does Sanofi - American Depositary Shares trade on?
Sanofi - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Sanofi - American Depositary Shares?
The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market
What is the current price of Sanofi - American Depositary Shares?
The current price of Sanofi - American Depositary Shares is 47.47
When was Sanofi - American Depositary Shares last traded?
The last trade of Sanofi - American Depositary Shares was at 01/15/26 04:00 PM ET
What is the market capitalization of Sanofi - American Depositary Shares?
The market capitalization of Sanofi - American Depositary Shares is 59.37B
How many shares of Sanofi - American Depositary Shares are outstanding?
Sanofi - American Depositary Shares has 59B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>